Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q1 2018 financial results conference call and Annual and Special Meeting of shareholders on...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that experienced healthcare executive Dr. Laurence Terrisse-Rulleau is being proposed for election to Cipher's...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that Robert Tessarolo, President and Chief Executive Officer, will present at the 2018 Bloom Burton & Co....

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today provided a strategic and operational update and preliminary revenue results for the three months ended March 31, 2018. The...

Transaction broadens Cipher's Canadian dermatology portfolio with first and only prescription product for raised seborrheic keratoses (SKs) MISSISSAUGA, ON, April 6, 2018 /CNW/ - Cipher...

Cipher to Acquire Cardiome's Canadian Business Portfolio, Comprised of Four Commercial and Pipeline Assets Targeting Cardiovascular and Anti-Infective Indications for Upfront Consideration of...

90% increase in revenue and 214% increase in income from continuing operations for Q4 2017 Canadian launch of OZANEX™ in Jan 2018 Acquired Canadian rights to TRULANCE® in Feb 2018 MISSISSAUGA, ON,

A new differentiated treatment option for GI disorders Transaction broadens Cipher's Canadian portfolio providing entry into rapidly growing market where innovative treatments are needed...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q4 and full-year 2017 financial results conference call on Wednesday, February 28, 2018. Q4 AND...

Cipher Pharmaceuticals Inc. (TSX:CPH) today announced it has entered into an exclusive distribution and supply agreement with Italmex Pharma S.A. ("Italmex") under which Cipher has granted Italmex...

Cipher Pharmaceuticals Inc. (TSX:CPH) today announced the Canadian launch of OZANEX™ (ozenoxacin cream, 1%), a novel bactericidal topical antibiotic cream indicated for the treatment of impetigo...

Substantially reduces cost of capital and interest expense, provides additional capacity to support future growth MISSISSAUGA, ON, Nov. 3, 2017 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH)...

Strong Q3 performance 29% revenue growth and 77% growth in income from continuing operations Production resumes at Puerto Rico manufacturing facilities MISSISSAUGA, ON, Nov. 3, 2017 /CNW/ - Cipher...

In the news release, Notice of Cipher Pharmaceuticals Q2 2017 conference call, issued today at 09:32, please note that an error occurred in the headline which should read "Notice of Cipher...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today commented on the impact from Hurricane Maria to its manufacturing partner's facilities in Puerto Rico. Galephar...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today commented on a warning letter issued to Cipher by the Office of Prescription Drug Promotion of the U.S. Food and Drug...

Company achieves important strategic milestones, delivers strong financial results MISSISSAUGA, ON, Aug. 11, 2017 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q2 2017 financial results conference call on Friday, August 11, 2017. Q2 2017 CONFERENCE CALL...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that Chris Watters has joined the Company in the new position of Vice President, Corporate Development. Mr....

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company"), in accordance with Toronto Stock Exchange requirements, announced the voting results from its Annual Meeting of Shareholders held...

Results highlighted by 92% increase in Adjusted EBITDA, 18% increase in revenue MISSISSAUGA, ON, May 11, 2017 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today...

Cipher Pharmaceuticals Inc. (TSX:CPH) today announced the Health Canada approval of OZANEX™ (ozenoxacin cream, 1%) a novel topical antibiotic indicated for the treatment of impetigo in patients...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced that it has completed an agreement (the "Agreement") to sell substantially all of the assets of Cipher...

Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced the details of its Q1 2017 financial results conference call and Annual Meeting of shareholders on Thursday, May...

Mark Beaudet expected to be appointed new independent Chair of Board MISSISSAUGA, ON, April 12, 2017 /CNW/ - Cipher Pharmaceuticals Inc. (TSX:CPH) ("Cipher" or "the Company") today announced...